Abstract: The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant.

Abstract: The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.

Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.

Abstract: Immunostimulatory combination are provided comprising: (i) a TLR agonist, (ii) a CD40 agonist, and (iii) an antigen, wherein said antigen consists of one or more antigenic peptides which range in size from 6-14 amino acids in length, wherein these moieties are each present in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. The use of such short peptides unexpectedly enhances CD8+ T cell immunity.

Abstract: Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.

Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.

Abstract: The invention is directed to a method for the production of a pertussis vaccine and, in particular, a detoxified pertussis vaccine comprising detoxified pertussis toxin (PT), detoxified pertussis lipopolysaccharide (P-LPS), and detoxified pertussis adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.

Abstract: A persimmon leaf-derived polysaccharide fraction consisting of 60-80 wt % of neutral sugar and 18-39 wt % of uronic acid, and 0.5-10 wt % of 3-deoxy-D-manno-2-octulosonic acid (KDO) analogs, the wt % based on the total weight of the polysaccharide fraction.

Abstract: The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TAM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as flavivirus infection.

Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Abstract: The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle.

Abstract: The disclosure relates generally to methods and compositions of treating or preventing diabetes mellitus by administering to a subject a composition comprising an amount of stem and/or progenitor cells and at least one antigen-specific therapy.

Abstract: The present invention relates more specifically to a cosmetic treatment method intended in particular to improve the appearance of the skin and/or hair comprising the simultaneous and/or sequential administration: a) of at least one cytochrome C oxidase substrate and/or of at least one agent which increases the expression of the said substrate; and b) of at least one light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase. In particular, the said light radiation exhibits at least one predominant wavelength which activates cytochrome C oxidase ranging from 550 to 1000 nm, in particular from 550 to 800 nm, preferably from 620 to 700 nm and more preferably still from 640 to 680 nm and is preferably used at a dose ranging from 0.01 to 200 J/cm2, preferably from 0.1 to 30 J/cm2, more preferably from 1 to 30 J/cm2, indeed even from 5 to 30 J/cm2.

Abstract: The present invention discloses a composition(s) of hydrophobic plant molecule(s) and/or extract(s) with enhanced bioavailability comprising hydrophobic active and synergetic combination of lecithin and lysolecithin and to the process for preparation thereof.

Abstract: A composition, in aqueous solution, comprising insulin in hexameric form, at least one substituted anionic compound and at least one polyanionic compound, said substituted anionic compound consisting of a discrete number n of between 1 and 8 of identical or different saccharide units, linked via identical or different glycoside bonds, said saccharide unit or one of said saccharide units being in open, oxidized or reduced form, said compound comprising salifiable carboxyl groups and said substituted anionic compound bearing on its reductive chain end at least one radical AA resulting from an aromatic amino acid comprising a phenyl or an indole, which may or may not be substituted, or an aromatic amino acid derivative comprising a phenyl or an indole, which may or may not be substituted.

Abstract: A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity.

Abstract: The invention relates to solid compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid, and methods of making and using such solid compositions.

Abstract: The present invention provides methods and compositions for treating pediatric solid tumor by administering a composition comprising nanoparticles that comprise a taxane and an albumin.

Abstract: The present invention relates to compositions and methods for the administration of Cannabinoids to a patient, and in a specific embodiment, the compositions and methods may utilize or include cannabinoids, and one or more active pharmaceutical ingredients, wherein said composition is configured for transdermal or oral delivery.

Abstract: The invention relates to fatty acid statin conjugates and fatty acid FXR agonist conjugates; compositions comprising an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate.

Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.

Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Abstract: This disclosure relates to intranasal administration of conjugates comprising guanidinylated aminoglycosides (“guanidinoglycosides”) and a polypeptide (e.g., an enzyme, antibody, or polypeptide growth factor). For example, such administration methods are useful for delivering a polypeptide to the brain and/or cerebrospinal fluid. Such methods are useful for treating a lysosomal storage disease through intranasal administration of a conjugate comprising one or more guanidinoglycosides and an enzyme useful for treating a lysosomal storage disease.

Abstract: The invention relates to dendrimers conjugated to multiple targeting peptides and one or more therapeutic, diagnostic, or imaging agents for delivery of such agents across the blood-brain barrier and into certain cell types including, cells expressing the LRP-1 receptor. Also described are methods of making compounds that comprise dendrimers conjugated to targeting peptides and therapeutic, diagnostic, or imaging agents.

Abstract: Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed.

Abstract: The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens/therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis.

Abstract: Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and fir treating viral infections and other diseases.

Abstract: The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.

Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.

Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.

Abstract: The present disclosure provides anti-CD22 antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.

Abstract: Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I, L-(T-A-D)n ??I wherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II. wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.

Abstract: A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.

Abstract: The present invention relates to the field of cancer treatment, particularly to a novel constructs useful for treating tumors expressing H19 and/or IGF-II. More specifically, the invention provides compositions and methods utilizing a nucleic acid construct enabling expression of a cytotoxic gene product directed by more than one tumor specific promoter.

Abstract: The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.

Abstract: A composition for use in radiology includes glass micro bubbles, Araldite, Jeffamine, magnesium oxide, and polyethylene. Another composition or use in radiology may include glass micro bubbles, an epoxy, acrylic, or polyurethane, and polyethylene. This composition may result in an elemental composition including carbon, oxygen, hydrogen, nitrogen, calcium, and magnesium. A composition for use in radiology may include glass micro bubbles, araldite, jeffamine, calcium carbonate, magnesium oxide, polyethylene, and a pigment and the composition includes an elemental composition including carbon, oxygen, hydrogen, nitrogen, calcium, silicon, and magnesium.

Abstract: The present invention provides new methods for cardiac imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides a method for the treatment or prevention of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides methods for monitoring the effect of cancer treatment on the heart, and/or methods for monitoring a cancer treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for a test or treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug. In some embodiments, the present invention provides methods for determining the risk of a cardiovascular disease, for assessing risk of a cardiovascular disease, and/or for determining the risk of heart attack.

Abstract: A thio-selective radioactive labeling agent has the following general formula: *R-L-VS, wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.

Abstract: An approach to hyperthermia for cancer treatment based on multiphonon relaxation of optical excitation in rare-earth (particularly Dy3+) doped nanocrystals after laser irradiation allows fast and accurate local heating to a preset temperature. A collection of nanoparticles suitable for use in hyperthermia treatment of cancerous and non-cancerous cells by laser irradiation in the wavelength of the transparency window of biological tissue (800 nm-1300 nm) preferably 800-900 nm is provided, where each nanoparticle comprises a crystalline host structure, and at least one species of rare-earth dopant ion.

Abstract: A device for pathogen inactivation on an object may include a main body defining an internal space; and a first light source provided on a first internal surface of the main body. The first light source may light having a wavelength in the range of 400 nm to 500 nm. The internal space accommodates the object. A handheld device to inactivate pathogens may include a main body; a light source; a power source; and control electronics to control activation of the light source based on input from the user. The light source may light having a wavelength in the range of 400 nm to 500 nm. A method for inactivating pathogens on a surface may include positioning a light source at a predetermined distance from the surface and illuminating the surface with 400-500 nm light for a predetermined amount of time.

Abstract: A condenser assembly for a chamber of a sterilization system is provided which includes a cooling apparatus operable within the chamber and external means for receiving exhaust air and vapors from the chamber and for separating vapors into water and air. The external means may include an air-water separator or a condenser. The cooling apparatus is operable during at least one phase or cycle of a sterilization process to reduce the temperature inside the chamber and increase the condensation of vapors inside the chamber. A method of treating articles in a sterilization system with the condenser assembly includes disinfecting the articles in a chamber and, after disinfecting, recondensing vapor within the chamber using the cooling apparatus.

Abstract: Solutions for limiting the undesirable spread of pathogens by indirect contact are provided. The solutions involve heat-sanitization of contact regions on articles or fixtures by flowing selected electromagnetic radiation energy through underlying waveguide structures substantially parallel to the contact regions.

Abstract: A plasma device and an air conditioner including a plasma device are provided. The plasma device may include a substrate body, a first electrode disposed on one or a first surface of the substrate body to perform plasma discharge, and a second electrode disposed on the other or a second surface of the substrate body to act with the first electrode. The substrate body may include a third electrode that acts with the first electrode or the second electrode to perform the plasma discharge, and an insulator that surrounds the third electrode.

Abstract: A sanitizing floor mat for sanitizing a user's shoes when the user steps thereon in order to prevent the spread of germs and bacteria on the user's shoes. The sanitizing floor mat includes a body that is substantially planar so that it can be placed flush on the floor, wherein the mat is preferably placed in the threshold of a doorway. The body is composed of an absorbent material and is impregnated with a disinfecting solution. The disinfecting solution is preferably an antiseptic solution. A base layer is disposed on an underside of the body, wherein the base layer is composed of a high-friction material so as to prevent the sanitizing floor mat from slipping on the floor.

Abstract: An oxidizing agent generating device and a liquid application device combine a gaseous oxidizing agent with a liquid creating an oxidizing agent-liquid material that is applied to a surface to incapacitate and destroy pathogens on the surface. The oxidizing agent ozone is combined with the liquid and the mixture is applied under pressure to the surface to render the pathogens ineffective. A surfactant is added to the mixture decreasing the tension of the mixture when it is in contact with the surface increasing the amount of dissolved ozone in contact with the surface.

Abstract: A method and system for the decontamination of poultry houses between flocks where the building is evacuated of all animals and people, and the poultry house, in particular the bedding, is saturated with high levels of ozone, preferably using a portable and transportable ozone supply and delivery system. A tarp may be used over top of the bedding and the ozone delivered beneath the tarp to concentrate the ozone to the bedding. The system may also be used to decontaminate water lines in the poultry house.

Abstract: An air freshener is configured to be carried by a power outlet of an automobile. The air freshener includes a scent capsule disposed in a housing. A heat source is disposed in the housing adjacent and opposing a permeable membrane of the scent capsule. The heat source is configured to heat the fragrant material in the scent capsule and accelerate permeation of the fragrant material through the permeable membrane of the sent capsule. A hatch is pivotally coupled to the housing and substantially contained within a hatch cavity with an outer surface that is substantially flush with an exterior of the housing in a closed position. The hatch can include a capsule cavity therein, carrying the scent capsule, and facing an interior of the housing in the closed position.

Abstract: A sterilization and deodorization apparatus is provided. The sterilization and deodorization apparatus may include a frame that defines an outer appearance of the sterilization and deodorization apparatus, a plasma unit or device disposed on or at one or a first side of the frame, the plasma unit forming a plasma region to generate a plurality of ions, and a filter unit or filter disposed on the other or a second side of the frame which is spaced apart from the frame. The filter unit may include a filter frame having a plurality of through-holes so that air passes therethrough, and a photocatalyst applied to the filter frame to perform photocatalytic reaction.

Abstract: A molded retainer and a method for making the molded retainer are provided. The molded retainer includes a body defining a coupling sleeve, molded from a plastic material and defined by one or more sidewalls. An axial opening is formed in the sleeve about a central axis and at least one transverse engagement opening is formed in the sidewall. An engagement member is integrally molded with the retainer body and is pivotably attached to the sidewall within the engagement opening. The engagement member is pivotable between a first position and a second position, wherein in the first position at least a portion of the engagement member is positioned within the axial opening for engagement with a structure positioned within the axial opening.